5 research outputs found
Isolation and characterization of exosome-enriched urinary extracellular vesicles from Dent's disease type 1 Spanish patients
Enfermedad de Dent; Exosomas; Vesículas extracelularesDent's disease; Exosomes; Extracelular vesiclesMalaltia de Dent; Exosomes; Vesícules extracel·lularsAntecedentes y objetivo
La enfermedad de Dent tipo 1 (DD1) es una enfermedad hereditaria rara ligada al cromosoma X causada por mutaciones en el CLCN5 que se caracteriza principalmente por una disfunción del túbulo proximal, hipercalciuria, nefrolitiasis o nefrocalcinosis, enfermedad renal crónica progresiva y proteinuria de bajo peso molecular, rasgo distintivo de la enfermedad. En la actualidad no existe un tratamiento curativo específico, únicamente sintomático, y no previene la progresión de la enfermedad. En este estudio hemos aislado y caracterizado las vesículas extracelulares urinarias (uEV) enriquecidas en exosomas que nos permitirán identificar biomarcadores asociados a la progresión de DD1 y ayudarán a una mejor comprensión de las bases fisiopatológicas.
Materiales y métodos
A través de una convocatoria nacional de la Sociedad Española de Nefrología (SEN) y la Sociedad Española de Nefrología Pediátrica (AENP), se obtuvieron orinas de pacientes y controles de distintos hospitales españoles, las cuales se procesaron para obtener los uEV. Los datos de estos pacientes fueron proporcionados por los respectivos nefrólogos o extraídos del registro RENALTUBE. Los uEV se aislaron mediante ultracentrifugación, fueron caracterizados morfológicamente y se extrajo su contenido de proteína y micro-ARN.
Resultados
Se seleccionó a 25 pacientes y 10 controles, de los cuales se procesaron las orinas para aislar los uEV. Nuestros resultados mostraron que la concentración relativa de uEV/ml era menor en los pacientes que en los controles (0,26 × 106 vs. 1,19 × 106 uEV/ml; p < 0,01). Además, se vio que los uEV de los pacientes eran significativamente más grandes que los de los sujetos control (diámetro medio: 187,8 vs. 143,6 nm; p < 0,01). Por último, nuestros datos demostraron que se había extraído correctamente el ARN tanto de los exosomas de pacientes como de los controles.
Conclusiones
En este trabajo describimos el aislamiento y caracterización de uEV de pacientes con DD 1 y controles sanos, útiles para el posterior estudio de moléculas cargo diferencialmente expresadas en esta enfermedad.Background and objectives
Dent's disease type 1 (DD1) is a rare X-linked hereditary pathology caused by CLCN5 mutations that is characterized mainly by proximal tubule dysfunction, hypercalciuria, nephrolithiasis/nephrocalcinosis, progressive chronic kidney disease, and low-weight proteinuria, the molecular hallmark of the disease. Currently, there is no specific curative treatment, only symptomatic and does not prevent the progression of the disease. In this study we have isolated and characterized urinary extracellular vesicles (uEVs) enriched in exosomes that will allow us to identify biomarkers associated with DD1 progression and a better understanding of the pathophysiological bases of the disease.
Materials and methods
Through a national call from the Spanish Society of Nephrology (SEN) and the Spanish Society of Pediatric Nephrology (AENP), urine samples were obtained from patients and controls from different Spanish hospitals, which were processed to obtain the uEVs. The data of these patients were provided by the respective nephrologists and/or extracted from the RENALTUBE registry. The uEVs were isolated by ultracentrifugation, morphologically characterized and their protein and microRNA content extracted.
Results
Twenty-five patients and 10 controls were recruited, from which the urine was processed to isolate the uEVs. Our results showed that the relative concentration of uEVs/ml is lower in patients compared to controls (0.26 × 106 vs. 1.19 × 106 uEVs/ml, P < 0.01). In addition, the uEVs of the patients were found to be significantly larger than those of the control subjects (mean diameter: 187.8 vs. 143.6 nm, P < 0.01). Finally, our data demonstrated that RNA had been correctly extracted from both patient and control exosomes.
Conclusions
In this work we describe the isolation and characterization of uEVs from patients with DD1 and healthy controls, that shall be useful for the subsequent study of differentially expressed cargo molecules in this pathology.Este trabajo ha sido financiado principalmente por la fundación SENEFRO (SEN2019 a AM), por ASDENT y por subvenciones del Ministerio de Ciencia e Innovación (SAF201789989 a AM) y de la Red de Investigación Renal REDinREN (12/0021/0013). El Grupo de Fisiopatología Renal tiene la Mención de Calidad de la Generalitat de Cataluña (2017 SGR)
Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors
Pancreatic neuroendocrine tumors (PanNETs) are rare in von Hippel-Lindau disease (VHL) but cause serious morbidity and mortality. Management guidelines for VHL-PanNETs continue to be based on limited evidence, and survival data to guide surgical management are lacking. We established the European-American-Asian-VHL-PanNET-Registry to assess data for risks for metastases, survival and long-term outcomes to provide best management recommendations. Of 2330 VHL patients, 273 had a total of 484 PanNETs. Median age at diagnosis of PanNET was 35 years (range 10-75). Fifty-five (20%) patients had metastatic PanNETs. Metastatic PanNETs were significantly larger (median size 5 vs 2 cm; P = 2.8 cm. Codons 161 and 167 were hotspots for VHL germline mutations with enhanced risk for metastatic PanNETs. Multivariate prediction modeling disclosed maximum tumor diameter and TVDT as significant predictors for metastatic disease (positive and negative predictive values of 51% and 100% for diameter cut-off >= 2.8 cm, 44% and 91% for TVDT cut-off of 1.5 cm in diameter were operated. Ten-year survival was significantly longer in operated vs non-operated patients, in particular for PanNETs = 2.8 cm (94% vs 85% by 10 years; P = 0.020; 80% vs 50% at 10 years; P = 0.030). This study demonstrates that patients with PanNET approaching the cut-off diameter of 2.8 cm should be operated. Mutations in exon 3, especially of codons 161/167 are at enhanced risk for metastatic PanNETs. Survival is significantly longer in operated non-metastatic VHL-PanNETs
Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2:an international retrospective population-based study
Background The prevention of medullary thyroid cancer in patients with multiple endocrine neoplasia type 2 syndrome has demonstrated the ability of molecular diagnosis and prophylactic surgery to improve patient outcomes. However, the other major neoplasia associated with multiple endocrine neoplasia type 2, phaeochromocytoma, is not as well characterised in terms of occurrence and treatment outcomes. In this study, we aimed to systematically characterise the outcomes of management of phaeochromocytoma associated with multiple endocrine neoplasia type 2.Methods This multinational observational retrospective population-based study compiled data on patients with multiple endocrine neoplasia type 2 from 30 academic medical centres across Europe, the Americas, and Asia. Patients were included if they were carriers of germline pathogenic mutations of the RET gene, or were first-degree relatives with histologically proven medullary thyroid cancer and phaeochromocytoma. We gathered clinical information about patients' RET genotype, type of treatment for phaeochromocytoma (ie, unilateral or bilateral operations as adrenalectomy or adrenal-sparing surgery, and as open or endoscopic operations), and postoperative outcomes (adrenal function, malignancy, and death). The type of surgery was decided by each investigator and the timing of surgery was patient driven. The primary aim of our analysis was to compare disease-free survival after either adrenal-sparing surgery or adrenalectomy.Findings 1210 patients with multiple endocrine neoplasia type 2 were included in our database, 563 of whom had phaeochromocytoma. Treatment was adrenalectomy in 438 (79%) of 552 operated patients, and adrenal-sparing surgery in 114 (21%). Phaeochromocytoma recurrence occurred in four (3%) of 153 of the operated glands after adrenal-sparing surgery after 6-13 years, compared with 11 (2%) of 717 glands operated by adrenalectomy (p=0.57). Postoperative adrenal insufficiency or steroid dependency developed in 292 (86%) of 339 patients with bilateral phaeochromocytoma who underwent surgery. However, 47 (57%) of 82 patients with bilateral phaeochromocytoma who underwent adrenal-sparing surgery did not become steroid dependent.Interpretation The treatment of multiple endocrine neoplasia type 2-related phaeochromocytoma continues to rely on adrenalectomies with their associated Addisonian-like complications and consequent lifelong dependency on steroids. Adrenal-sparing surgery, a highly successful treatment option in experienced centres, should be the surgical approach of choice to reduce these complications.</p
Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study
Background The prevention of medullary thyroid cancer in patients with
multiple endocrine neoplasia type 2 syndrome has demonstrated the
ability of molecular diagnosis and prophylactic surgery to improve
patient outcomes. However, the other major neoplasia associated with
multiple endocrine neoplasia type 2, phaeochromocytoma, is not as well
characterised in terms of occurrence and treatment outcomes. In this
study, we aimed to systematically characterise the outcomes of
management of phaeochromocytoma associated with multiple endocrine
neoplasia type 2.
Methods This multinational observational retrospective population-based
study compiled data on patients with multiple endocrine neoplasia type 2
from 30 academic medical centres across Europe, the Americas, and Asia.
Patients were included if they were carriers of germline pathogenic
mutations of the RET gene, or were first-degree relatives with
histologically proven medullary thyroid cancer and phaeochromocytoma. We
gathered clinical information about patients’ RET genotype, type of
treatment for phaeochromocytoma (ie, unilateral or bilateral operations
as adrenalectomy or adrenal-sparing surgery, and as open or endoscopic
operations), and postoperative outcomes (adrenal function, malignancy,
and death). The type of surgery was decided by each investigator and the
timing of surgery was patient driven. The primary aim of our analysis
was to compare disease-free survival after either adrenal-sparing
surgery or adrenalectomy.
Findings 1210 patients with multiple endocrine neoplasia type 2 were
included in our database, 563 of whom had phaeochromocytoma. Treatment
was adrenalectomy in 438 (79%) of 552 operated patients, and
adrenal-sparing surgery in 114 (21%). Phaeochromocytoma recurrence
occurred in four (3%) of 153 of the operated glands after
adrenal-sparing surgery after 6-13 years, compared with 11 (2%) of 717
glands operated by adrenalectomy (p=0.57). Postoperative adrenal
insufficiency or steroid dependency developed in 292 (86%) of 339
patients with bilateral phaeochromocytoma who underwent surgery.
However, 47 (57%) of 82 patients with bilateral phaeochromocytoma who
underwent adrenal-sparing surgery did not become steroid dependent.
Interpretation The treatment of multiple endocrine neoplasia type
2-related phaeochromocytoma continues to rely on adrenalectomies with
their associated Addisonian-like complications and consequent lifelong
dependency on steroids. Adrenal-sparing surgery, a highly successful
treatment option in experienced centres, should be the surgical approach
of choice to reduce these complications
Comparison of Pheochromocytoma-Specific Morbidity and Mortality Among Adults With Bilateral Pheochromocytomas Undergoing Total Adrenalectomy vs Cortical-Sparing Adrenalectomy
WOS: 000482143700031PubMed ID: 31397861IMPORTANCE Large studies investigating long-term outcomes of patients with bilateral pheochromocytomas treated with either total or cortical-sparing adrenalectomies are needed to inform clinical management. OBJECTIVE To determine the association of total vs cortical-sparing adrenalectomy with pheochromocytoma-specific mortality, the burden of primary adrenal insufficiency after bilateral adrenalectomy, and the risk of pheochromocytoma recurrence. DESIGN, SETTING, AND PARTICIPANTS This cohort study used data from a multicenter consortium-based registry for 625 patients treated for bilateral pheochromocytomas between 1950 and 2018. Data were analyzed from September 1, 2018, to June 1, 2019. EXPOSURES Total or cortical-sparing adrenalectomy. MAIN OUTCOMES AND MEASURES Primary adrenal insufficiency, recurrent pheochromocytoma, and mortality. RESULTS Of 625 patients (300 [48%] female) with a median (interquartile range [IQR]) age of 30 (22-40) years at diagnosis, 401 (64%) were diagnosed with synchronous bilateral pheochromocytomas and 224 (36%) were diagnosed with metachronous pheochromocytomas (median [IQR] interval to second adrenalectomy, 6 [1-13] years). In 505 of 526 tested patients (96%), germline mutationswere detected in the genes RET (282 patients [54%]), VHL (184 patients [35%]), and other genes (39 patients [7%]). Of 849 adrenalectomies performed in 625 patients, 324 (52%) were planned as cortical sparing and were successful in 248 of 324 patients (76.5%). Primary adrenal insufficiency occurred in all patients treated with total adrenalectomy but only in 23.5% of patients treated with attempted cortical-sparing adrenalectomy. A third of patients with adrenal insufficiency developed complications, such as adrenal crisis or iatrogenic Cushing syndrome. Of 377 patients who became steroid dependent, 67 (18%) developed at least 1 adrenal crisis and 50 (13%) developed iatrogenic Cushing syndrome during median (IQR) follow-up of 8 (3-25) years. Two patients developed recurrent pheochromocytoma in the adrenal bed despite total adrenalectomy. In contrast, 33 patients (13%) treated with successful cortical-sparing adrenalectomy developed another pheochromocytoma within the remnant adrenal after a median (IQR) of 8 (4-13) years, all of which were successfully treated with another surgery. Cortical-sparing surgery was not associated with survival. Overall survivalwas associated with comorbidities unrelated to pheochromocytoma: of 63 patients who died, only 3 (5%) died of metastatic pheochromocytoma. CONCLUSIONS AND RELEVANCE Patients undergoing cortical-sparing adrenalectomy did not demonstrate decreased survival, despite development of recurrent pheochromocytoma in 13%. Cortical-sparing adrenalectomy should be considered in all patients with hereditary pheochromocytoma